Insider buying last 90 days
No open-market insider purchases were filed for VCEL in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every VCEL insider filing, plotted on the chart in Gekko.Open VCEL in Gekko
NASDAQ: VCEL
Vericel (VCEL) Stock Analysis & Forecast
Oct 12 close
$40.62+0.52 (+1.3%)
Gekko Brief
AI summaryOct 12 closeThis week brings a trimmed price target from Argus, which cut its view on Vericel (VCEL) to $42.00, alongside continued attention to the company's cellular therapy business, which markets MACI, Epicel and NexoBrid for sports medicine and severe burn care. Commentary around the stock has shown mixed sentiment, with some posts noting frustration over recent performance even as shares ticked higher on the day.
VCEL closed at $40.62, up 1.3%, sitting between its 50-day average of $41.44 and 200-day average of $38.39. The GekkoIndex reads 58.9, placing the stock in the Neutral zone, with a 5-day change of 2.5. Price remains 17.3% below Gekko Fair Value of $49.14, a gap that stands out against the recent trend.
Vericel's next earnings report is scheduled for 5 November 2026, before the open, 24 days away and within a typical 20-trading-day holding window; the prior quarter saw a beat of $0.04 versus a $0.04 estimate with a reaction of -1.4%, and the company has beaten estimates in 6 of the last 8 quarters, with an average absolute reaction of 6.2%. Seasonality over this stretch of the calendar has averaged a 6.6% move across 5 years, rising in 4 of them. No insider, Congress or unusual options activity appears in the current window. Analyst coverage from 4 firms remains unanimously rated buy, with a consensus target of $60.57.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Vericel price vs fair value
Close $40.62200-day averageGekko Fair Value $49.14
Vericel quick facts
- Market cap
- $2.08B
- P/E ratio
- 85.2
- Forward P/E
- 57.1
- EPS, TTM
- $0.47
- Revenue, TTM
- $306.3M
- Profit margin
- 7.9%
- Dividend yield
- —
- Beta
- 1.02
- Volume
- 432,876 avg 564,204
- 1-year return
- +24.0%
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±7.5%
- 50-day average
- $41.44
- 200-day average
- $38.39
- Next earnings
- Nov 5 before open
- Shares outstanding
- 51.21M
Vericel swing-trade checklist
Vericel scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $40.62 sits between the 50-day ($41.44) and 200-day ($38.39) averages, or the averages disagree.
See the chart - GekkoIndexmixed
58.9, Neutral
Reading 58.9 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
17.3% below
Price is 17.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+6.6% on average
From this point in the calendar, the next 20 trading days averaged +6.6% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Vericel stock chart and price history
Vericel closed at $40.62 on Oct 12, 2026, +24.0% over the past year, inside a 52-week range of $28.95 to $49.32.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +5.9%
- 3 months
- −11.9%
- 6 months
- +17.9%
- 1 year
- +24.0%
The full VCEL chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open VCEL in Gekko
Follow Vericel through every session
Put VCEL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track VCEL in GekkoFree for 7 days. No credit card required.
About Vericel
Vericel develops and sells cell-based therapies, focusing on sports medicine and severe burn treatment in the United States. The company is best known for MACI, a cartilage repair product used to treat knee damage, and Epicel, a skin replacement for deep burns in both adults and children. It is also working to bring NexoBrid, a product designed to clear dead tissue from thermal burns, through the registration process toward approval.
The company operates as a biopharmaceutical business that has moved past early research into selling approved products, while still advancing new treatments through development. Its work spans the full cycle of creating, producing, and distributing these therapies, with hospitals and clinicians treating orthopedic and burn patients representing its customer base.
Vericel traces its roots to 1989, when it was founded as Aastrom Biosciences, Inc., before adopting its current name. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ under the ticker VCEL.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- vcel.com
Vericel GekkoIndex: the smart money zone
Vericel’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58.9, in the Neutral zone, up 2.5 points over five sessions.
58.9Neutral
Up 2.5 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 25 | +4.3% | +6.3% | ||
| Accumulation | 277 | −0.3% | +0.5% | ||
| Neutral (current zone) | 337 | 0.0% | −0.2% | ||
| Distribution | 41 | +2.3% | +0.9% | ||
| Selling | 2 | Too few readings yet | |||
Average VCEL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the VCEL price, zone by zone.Track VCEL in Gekko
Is Vericel stock overvalued? Gekko Fair Value
Vericel trades 17.3% below Gekko Fair Value of $49.14, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Vericel shares are worth, recalculated every trading day.
$49.14
Gekko Fair Value, Oct 10, 2026
17.3% Undervalued
At the end of Aug 2026 the price was 27.5% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open VCEL in Gekko
Vericel insider and Congress trading
No open-market insider purchases were filed for Vericel, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in VCEL were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for VCEL, plotted on the chart in Gekko.Open VCEL in Gekko
Vericel earnings: next date and track record
Vericel reports on Nov 5, 2026, before the open (24 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, 24 days away
- EPS estimate
- $0.06
- Revenue estimate
- $77.98M
6 of 8reports beat the EPS estimate
±6.2%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | $0.04 est −$0.04 | $77.46M est $72.70M | −1.4% |
| May 7, 2026 | −$0.12 est −$0.16 | $68.43M est $63.68M | −9.0% |
| Feb 26, 2026 | $0.45 est $0.45 | $92.92M est $90.97M | −3.8% |
| Nov 6, 2025 | $0.10 est −$0.02 | $67.50M est $92.66M | +4.7% |
| Jul 31, 2025 | −$0.01 est −$0.04 | $63.24M est $64.57M | −12.4% |
| May 8, 2025 | −$0.23 est −$0.15 | $52.60M est $64.81M | +3.1% |
| Feb 27, 2025 | $0.38 est $0.34 | $75.38M est $58.12M | −3.0% |
| Nov 7, 2024 | −$0.02 est −$0.05 | $57.91M est $77.97M | +12.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Vericel stock forecast and analyst price targets
Analysts’ average 12-month price target for Vericel is $60.57, +49.1% from the last close, from 4 firms rating the stock in the last 90 days.
$60.57consensus 12-month target, +49.1% from the last close
Now $40.62Avg $60.57
Low $58High $72
Each firm’s latest rating in the last 90 days: 4 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 18 | Leerink Partners | $59 | +45.2% |
| Sep 4 | TD Cowen | $58 | +42.8% |
| Aug 20 | Truist Financial | — | — |
| Jul 31 | Truist Financial | $58 | +42.8% |
| Jul 31 | H.C. Wainwright | $72 | +77.3% |
−0.2%average 20-day move after past Neutral readings
+6.6%average move over the next 20 trading days in the last 5 years
±3.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Vericel seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Vericel averaged +6.6% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.8% | 5 of 5 |
| Next 10 trading days | +5.0% | 5 of 5 |
| Next 15 trading days | +5.6% | 4 of 5 |
| Next 20 trading days | +6.6% | 4 of 5 |
| Next 30 trading days | +7.8% | 3 of 5 |
For scale, VCEL’s typical 20-trading-day move in either direction is about 7.5%.
Vericel market cap and key statistics
Vericel’s market cap is $2.08B, with a P/E ratio of 85.2 and revenue of $306.3M over the last twelve months.
Valuation
- Market cap
- $2.08B
- P/E ratio
- 85.2
- Forward P/E
- 57.1
- EPS, TTM
- $0.47
- Gekko Fair Value
- $49.14
Trading
- Volume
- 432,876
- Avg volume, 20 days
- 564,204
- 52-week high
- $49.32
- 52-week low
- $28.95
- Shares outstanding
- 51.21M
Financials
- Revenue, TTM
- $306.3M
- Profit margin
- 7.9%
- Return on equity
- 7.2%
- Quarterly earnings growth, YoY
- +18.9%
Risk and income
- Beta
- 1.02
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±7.5%
Vericel stock news this week
Coverage of Vericel this week reads neutral: 1 positive, 1 neutral and 1 negative headlines.
- Vericel Corporation (VCEL) Stock ForecastsYahoo! Finance Canada, Oct 8
- VCEL: Vericel Corp Latest Stock Price, Analysis, News and Trading IdeasStocktwits, Oct 7
- Vericel Corporation (VCEL) Stock Price, News, Quote & HistoryYahoo! Finance Canada, Oct 7
Vericel peers
Vericel’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Vericel stock FAQ
What is Vericel’s market cap?
Vericel’s market cap is $2.08B at the Oct 12, 2026 close of $40.62, with 51.21M shares outstanding. The shares trade on a P/E ratio of 85.2.
What is the Vericel stock forecast?
The consensus analyst 12-month price target for Vericel is $60.57, +49.1% from the last close. Of the 4 firms that rated the stock in the last 90 days, 4 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Vericel stock overvalued or undervalued?
On Gekko’s estimate Vericel is undervalued: the Oct 12, 2026 close of $40.62 is 17.3% below Gekko Fair Value of $49.14. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Vericel report earnings next?
Vericel is expected to report on Nov 5, 2026, before the market opens (24 days away). Analysts expect earnings of $0.06 per share on revenue of $77.98M. Vericel beat the earnings estimate in 6 of its last 8 reports, moving 6.2% on average across the report.
What is Vericel’s 52-week high and low?
Vericel’s 52-week high is $49.32 and its 52-week low is $28.95; it closed at $40.62 on Oct 12, 2026, +24.0% over the past year. Over the last five years the shares peaked at $63.00 on Feb 5, 2025.
Is Vericel stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and seasonality), 2 as mixed (trend and gekkoindex) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Vericel the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.